Descriptors of multidrug-resistant TB deaths in Ethiopia-Reference-Cited by-同舟云学术

Descriptors of multidrug-resistant TB deaths in Ethiopia

Published:2023-12-01 Issue:4 Volume:13 Page:123-125
ISSN:2220-8372
Container-title:Public Health Action
language:en
Short-container-title:public health action

Author:

Tesema E.¹,Dememew Z. G.²,Datiko D. G.²,Gebreyohannes A.¹,Molla Y.²,Tefera A.¹,Gizatie G.¹,Bogale T.¹,Million M.¹,Suarez P. G.³,Aseressa M. M.³,Jerene D.⁴,Biru M.¹

Affiliation:

1. United States Agency for International Development (USAID) Eliminate TB Project, KNCV, Addis Ababa, Ethiopia

2. USAID Eliminate TB Project, MSH, Addis Ababa, Ethiopia

3. Management Sciences for Health, Global Health Systems Innovation, Arlington, VA, USA

4. KNCV Tuberculosis Foundation, The Hague, The Netherlands

Abstract

Deaths related to multidrug-resistant TB among patients who had received a second-line anti-TB drugs in Ethiopia were analysed. Respectively 38/704 (5.4%) and 44/995 (4.4%) deaths were identified in two cohorts (2015 and 2022). In the 2015 cohort, severe malnutrition was less prevalent, previous treatment rates were three times higher, hypokalaemia was more frequent, and the use of the Xpert® MTB/RIF assay, respiratory failure and severe anaemia/pancytopenia were less common than in the 2022 cohort. We observed that there were variations in adverse events when different treatment regimens were used over different time periods. To ensure proper patient care, correct guidance must be consistently implemented.

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference1 articles.

1. Risk factors for mortality among drug-resistant tuberculosis patients registered for drug-resistant treatment in Amhara region, Ethiopia: a historical cohort study